Researchers Find Potential Target for Drug to Treat Allergic Asthma – Newswise (press release)

Researchers Find Potential Target for Drug to Treat Allergic Asthma
Newswise (press release)
Newswise — COLUMBUS, Ohio – An enzyme that helps maintain immune system function by “throwing away” a specific protein has a vital role in controlling symptoms of allergic asthma, new research in mice suggests. The finding suggests that this enzyme, 

and more »

View full post on asthma – Google News

Researchers find potential target for drug to treat allergic asthma – Medical Xpress

Researchers find potential target for drug to treat allergic asthma
Medical Xpress
The finding suggests that this enzyme, called Cbl-b, could be a target for drugs used to treat allergic asthma and other autoimmune disorders. This new study, led by Ohio State University researchers, is the first to link Cbl-b to allergic asthma in an

and more »

View full post on asthma – Google News

Teva’s DuoResp Spiromax gets positive CHMP opinion to treat asthma and COPD – Pharmaceutical Business Review

Teva's DuoResp Spiromax gets positive CHMP opinion to treat asthma and COPD
Pharmaceutical Business Review
DuoResp Spiromax is a new multi-dose dry-powder inhaler with a combination of budesonide, an inhaled corticosteroid for the treatment of underlying inflammation in asthma and COPD, and formoterol fumarate dihydrate, a rapid-acting and long-lasting 
Teva's Symbicort generic backed for EU approvalPMLiVE
10 new medicines recommended for approval in EuropePharmaTimes

all 3 news articles »

View full post on asthma – Google News

Teva Gets Positive CHMP Opinion For DuoResp Spiromax To Treat Asthma And … – RTT News

Teva Gets Positive CHMP Opinion For DuoResp Spiromax To Treat Asthma And
RTT News
DuoResp Spiromax is a new multi-dose dry-powder inhaler with a combination of budesonide, an inhaled corticosteroid to treat the underlying inflammation in asthma and COPD, and formoterol fumarate dihydrate, a rapid-acting and long-lasting beta2 
EU Agency backs respiratory drugs for approvalReuters UK
EMA Backs Generic Versions of AstraZeneca's SymbicortBloomberg

all 7 news articles »

View full post on asthma – Google News

Teva Gets Positive CHMP Opinion For DuoResp Spiromax To Treat Asthma And … – NASDAQ

Teva Gets Positive CHMP Opinion For DuoResp Spiromax To Treat Asthma And
NASDAQ
DuoResp Spiromax is a new multi-dose dry-powder inhaler with a combination of budesonide, an inhaled corticosteroid to treat the underlying inflammation in asthma and COPD, and formoterol fumarate dihydrate, a rapid-acting and long-lasting beta2 
UPDATE 1-EU Agency backs respiratory drugs for approvalReuters
EMA Backs Generic Versions of AstraZeneca's SymbicortBloomberg

all 7 news articles »

View full post on asthma – Google News